Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 74,034 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Debra Durso-Bumpus sold 74,034 shares of Blueprint Medicines stock in a transaction on Friday, June 21st. The stock was sold at an average price of $104.19, for a total value of $7,713,602.46. Following the completion of the sale, the insider now directly owns 43,763 shares of the company’s stock, valued at approximately $4,559,666.97. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Blueprint Medicines Trading Up 4.4 %

Blueprint Medicines stock opened at $108.52 on Friday. Blueprint Medicines Co. has a 12-month low of $43.89 and a 12-month high of $111.02. The firm has a market capitalization of $6.80 billion, a price-to-earnings ratio of -22.56 and a beta of 0.70. The firm has a 50 day moving average of $102.86 and a 200 day moving average of $92.45. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.32. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $96.12 million during the quarter, compared to analysts’ expectations of $82.58 million. As a group, research analysts predict that Blueprint Medicines Co. will post -5.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BPMC shares. The Goldman Sachs Group lifted their price objective on Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a report on Monday, May 6th. Stephens started coverage on shares of Blueprint Medicines in a report on Tuesday, May 14th. They set an “overweight” rating and a $140.00 price objective for the company. Leerink Partnrs upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating in a research report on Monday, May 6th. Piper Sandler lifted their target price on shares of Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $108.00.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of BPMC. Covestor Ltd grew its position in shares of Blueprint Medicines by 9,700.0% during the first quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 291 shares in the last quarter. Headlands Technologies LLC grew its holdings in Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 342 shares in the last quarter. Compass Wealth Management LLC bought a new stake in shares of Blueprint Medicines during the fourth quarter valued at approximately $69,000. Natixis purchased a new position in shares of Blueprint Medicines in the first quarter worth $73,000. Finally, Van ECK Associates Corp boosted its position in shares of Blueprint Medicines by 28.4% during the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 193 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.